Sangamo Therapeutics (NASDAQ:SGMO) Given Sell (E+) Rating at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (e+)" rating for Sangamo Therapeutics, indicating concerns about the company's stock performance.
• Despite the negative outlook from Weiss, other analysts have varied opinions, with Wall Street Zen upgrading to a "hold" rating and HC Wainwright maintaining a "buy" rating with a $10 target price.
• Sangamo reported a quarterly earnings miss with ($0.08) EPS, below the consensus estimate of ($0.07), and a revenue of $18.31 million compared to expectations of $31.68 million.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report)'s stock had its "sell (e+)" rating reiterated by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded Sangamo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, September 4th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $4.50.

Sangamo Therapeutics Trading Down 0.9%

Shares of Sangamo Therapeutics stock opened at $0.69 on Wednesday. The business has a 50-day moving average price of $0.56 and a two-hundred day moving average price of $0.58. Sangamo Therapeutics has a 1-year low of $0.41 and a 1-year high of $3.18. The company has a market cap of $208.69 million, a P/E ratio of -2.39 and a beta of 1.22.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The business had revenue of $18.31 million for the quarter, compared to analyst estimates of $31.68 million. Equities research analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several large investors have recently made changes to their positions in SGMO. R Squared Ltd acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at about $28,000. Cerity Partners LLC lifted its position in Sangamo Therapeutics by 439.2% in the 1st quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $36,000 after acquiring an additional 44,800 shares in the last quarter. Caption Management LLC bought a new position in Sangamo Therapeutics in the 1st quarter valued at about $37,000. XTX Topco Ltd bought a new position in Sangamo Therapeutics in the 2nd quarter valued at about $41,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Sangamo Therapeutics in the 1st quarter valued at about $47,000. 56.92% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.